JO3154B1 - عوامل مضادة لـ trpv4 - Google Patents

عوامل مضادة لـ trpv4

Info

Publication number
JO3154B1
JO3154B1 JOP/2012/0159A JOP20120159A JO3154B1 JO 3154 B1 JO3154 B1 JO 3154B1 JO P20120159 A JOP20120159 A JO P20120159A JO 3154 B1 JO3154 B1 JO 3154B1
Authority
JO
Jordan
Prior art keywords
trpv4
agents
isotopes
spiro
carbamate
Prior art date
Application number
JOP/2012/0159A
Other languages
English (en)
Inventor
Stoy Patrick
H Hoang Tram
R Patterson Jaclyn
Ye Guosen
Brooks Carl
B Goodman Krista
A Hilfiker Mark
Hammond Marlys
Cheung Mui
Schenck Eidam Hilary
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47558389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3154(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of JO3154B1 publication Critical patent/JO3154B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بنظائر سبيرو كربامات، وتركيبات صيدلانية تتضمنها واستخدامها كعوامل مضادة لـ TRPV4
JOP/2012/0159A 2011-06-17 2012-06-14 عوامل مضادة لـ trpv4 JO3154B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161498110P 2011-06-17 2011-06-17

Publications (1)

Publication Number Publication Date
JO3154B1 true JO3154B1 (ar) 2017-09-20

Family

ID=47558389

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0159A JO3154B1 (ar) 2011-06-17 2012-06-14 عوامل مضادة لـ trpv4

Country Status (38)

Country Link
US (1) US9187464B2 (ar)
EP (2) EP2721016B1 (ar)
JP (1) JP5969017B2 (ar)
KR (1) KR101870003B1 (ar)
CN (1) CN103732583B (ar)
AR (1) AR086958A1 (ar)
AU (1) AU2012284540B2 (ar)
BR (1) BR112013032391B1 (ar)
CA (1) CA2839743C (ar)
CL (1) CL2013003602A1 (ar)
CO (1) CO6821953A2 (ar)
CR (1) CR20130671A (ar)
CY (1) CY1117792T1 (ar)
DK (1) DK2721016T3 (ar)
DO (1) DOP2013000307A (ar)
EA (1) EA023616B1 (ar)
ES (2) ES2688733T3 (ar)
HR (1) HRP20160539T1 (ar)
HU (1) HUE029594T2 (ar)
IL (1) IL229872A (ar)
JO (1) JO3154B1 (ar)
MA (1) MA35184B1 (ar)
ME (1) ME02416B (ar)
MX (1) MX337440B (ar)
MY (1) MY173521A (ar)
PE (1) PE20141943A1 (ar)
PH (1) PH12013502463A1 (ar)
PL (1) PL2721016T3 (ar)
PT (1) PT2721016E (ar)
RS (1) RS54858B1 (ar)
SG (1) SG195106A1 (ar)
SI (1) SI2721016T1 (ar)
SM (1) SMT201600150B (ar)
TW (1) TWI538912B (ar)
UA (1) UA113963C2 (ar)
UY (1) UY34138A (ar)
WO (1) WO2013012500A1 (ar)
ZA (1) ZA201308816B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720546B1 (en) 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists
WO2012174340A1 (en) 2011-06-17 2012-12-20 Glaxosmithkline Llc Trpv4 antagonists
US9499533B2 (en) 2012-03-27 2016-11-22 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
JPWO2015046193A1 (ja) 2013-09-25 2017-03-09 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環式アミン誘導体
EP3458451B1 (en) * 2016-05-19 2020-06-03 Glaxosmithkline Intellectual Property (No. 2) Limited Trpv4 antagonist
US10968209B2 (en) 2016-05-19 2021-04-06 Glaxosmithkline Intellectual Property (No.2) Limited TRPV4 antagonist
KR102531344B1 (ko) 2016-10-03 2023-05-10 얀센 파마슈티카 엔.브이. Prmt5 억제제로서 사용하기 위한 신규의 모노사이클릭 및 바이사이클릭 고리 시스템 치환된 카르바뉴클레오시드 유사체
WO2018185701A1 (en) 2017-04-06 2018-10-11 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists as antitussive agents
CA3081424A1 (en) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Spirocyclic compounds as farnesoid x receptor modulators
WO2021170811A1 (en) 2020-02-27 2021-09-02 Glaxosmithkline Intellectual Property (No.2) Limited Method of treating eye disease using trpv4 antagonists
TWI899220B (zh) 2020-04-30 2025-10-01 日商拉夸里亞創藥股份有限公司 作為trpv4拮抗劑之嘧啶-4(3h)-酮衍生物
CN111704613B (zh) * 2020-06-23 2021-07-06 中国人民解放军军事科学院军事医学研究院 咪唑类衍生物及其作为trpv4抑制剂的用途
KR20230041680A (ko) * 2020-07-16 2023-03-24 라퀄리아 파마 인코포레이티드 안구 질환 치료제로서의 trpv4 억제제
CA3261160A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. COMPOUNDS AND THERAPEUTIC METHODS
CN119855818A (zh) * 2023-04-18 2025-04-18 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120435476A (zh) * 2023-04-18 2025-08-05 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120641413A (zh) * 2023-04-18 2025-09-12 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN120225516A (zh) * 2023-04-18 2025-06-27 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
CN121175303A (zh) * 2023-04-18 2025-12-19 河北乌图药业有限公司 化合物及其在慢性乙型肝炎、肝纤维化、肝癌的治疗中的应用
WO2025014818A1 (en) * 2023-07-07 2025-01-16 Actio Biosciences, Inc. Solid forms of gsk2798745, a trpv4 antagonist
CN117945917A (zh) * 2023-12-26 2024-04-30 衢州康鹏化学有限公司 一种3-氟-4-硝基苯甲酸的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69942801D1 (de) * 1998-05-26 2010-11-11 Chugai Pharmaceutical Co Ltd Heterozyklische indolderivate und mono- oder diazaindol-derivate
WO2005007648A2 (en) * 2003-07-16 2005-01-27 Neurogen Corporation Biaryl piperazinyl-pyridine analogues
KR20080070749A (ko) * 2005-11-23 2008-07-30 페인셉터 파마 코포레이션 개폐 이온 통로를 조절하기 위한 조성물 및 방법
WO2007067756A2 (en) 2005-12-08 2007-06-14 Amphora Discovery Corporation Certain chemical entities, compositions, and methods for modulating trpv1
AU2006327181A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
WO2008092891A1 (en) * 2007-02-01 2008-08-07 Glaxo Group Limited 1-oxa-3-azaspiro(4.5)decan-2-one derivatives for the treatment of eating disorders
GB0707934D0 (en) * 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
US7998982B2 (en) * 2007-08-09 2011-08-16 Abbott Laboratories Amide derivatives as TRPV1 antagonists
TW200944520A (en) * 2008-01-29 2009-11-01 Glaxo Group Ltd Spiro compounds as NPY Y5 receptor antagonists
EP2312947B1 (en) 2008-07-25 2014-01-01 GlaxoSmithKline LLC Trpv4 antagonists
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
US8742110B2 (en) * 2010-08-18 2014-06-03 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
EP2720546B1 (en) * 2011-06-17 2016-04-06 Glaxosmithkline Intellectual Property (No. 2) Limited Spiro-cyclic trpv4 antagonists
WO2012174340A1 (en) 2011-06-17 2012-12-20 Glaxosmithkline Llc Trpv4 antagonists

Also Published As

Publication number Publication date
EA201490037A1 (ru) 2015-12-30
WO2013012500A1 (en) 2013-01-24
SMT201600150B (it) 2016-07-01
KR101870003B1 (ko) 2018-06-22
BR112013032391A2 (pt) 2016-08-16
RS54858B1 (sr) 2016-10-31
EP2721016A1 (en) 2014-04-23
BR112013032391B1 (pt) 2020-11-24
CL2013003602A1 (es) 2014-07-04
ES2688733T3 (es) 2018-11-06
EA023616B1 (ru) 2016-06-30
CO6821953A2 (es) 2013-12-31
PT2721016E (pt) 2016-06-06
MX2013014898A (es) 2014-03-21
MY173521A (en) 2020-01-30
MA35184B1 (fr) 2014-06-02
SG195106A1 (en) 2013-12-30
SI2721016T1 (sl) 2016-06-30
EP3121177B1 (en) 2018-08-01
ME02416B (me) 2016-09-20
HRP20160539T1 (hr) 2016-06-17
US20140121206A1 (en) 2014-05-01
CR20130671A (es) 2014-02-04
EP3121177A1 (en) 2017-01-25
ES2569193T3 (es) 2016-05-09
KR20140041733A (ko) 2014-04-04
EP2721016B1 (en) 2016-04-06
MX337440B (es) 2016-03-03
AR086958A1 (es) 2014-02-05
UY34138A (es) 2013-01-03
AU2012284540B2 (en) 2014-08-28
HUE029594T2 (en) 2017-03-28
CA2839743C (en) 2017-03-28
TW201313705A (zh) 2013-04-01
JP2014518214A (ja) 2014-07-28
US9187464B2 (en) 2015-11-17
IL229872A (en) 2017-03-30
JP5969017B2 (ja) 2016-08-10
HK1195068A1 (zh) 2014-10-31
CN103732583A (zh) 2014-04-16
UA113963C2 (xx) 2017-04-10
ZA201308816B (en) 2015-02-25
AU2012284540A1 (en) 2013-04-04
PE20141943A1 (es) 2014-12-28
DOP2013000307A (es) 2014-06-01
CN103732583B (zh) 2015-12-23
NZ618221A (en) 2015-02-27
PL2721016T3 (pl) 2017-01-31
PH12013502463A1 (en) 2014-01-20
CA2839743A1 (en) 2013-01-24
DK2721016T3 (en) 2016-06-06
CY1117792T1 (el) 2017-05-17
EP2721016A4 (en) 2014-10-08
TWI538912B (zh) 2016-06-21

Similar Documents

Publication Publication Date Title
EA201490037A1 (ru) Антагонисты trpv4
JOP20180103A1 (ar) مركب صيدلاني
PH12016501151A1 (en) Nrf2 regulators
EA202190619A1 (ru) Противовирусные соединения
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CR20150370A (es) Compuestos antivirales
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
AR094204A1 (es) Composiciones para el cuidado oral que contienen haluros de acido amino
IN2015DN03029A (ar)
EA201590534A1 (ru) Новые бициклические производные
SV2014004771A (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2016006336A (es) Compuestos pirazolopirimidina.
BR112015012907A2 (pt) composição de cuidado pessoal
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
ECSP15013883A (es) Benzamidas
EA201590731A1 (ru) Антитела к гемагглютинину и способы применения
EA201590887A1 (ru) Композиция
EP2702989A4 (en) STABLE PHARMACEUTICAL COMPOSITION
EP2815752A4 (en) ORAL PHARMACEUTICAL COMPOSITION
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
UY34158A (es) Composicion herbicida